Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) Equity Ratio (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Equity Ratio for 5 consecutive years, with 0.89 as the latest value for Q3 2020.

  • On a quarterly basis, Equity Ratio rose 2054.41% to 0.89 in Q3 2020 year-over-year; TTM through Sep 2020 was 0.89, a 2054.41% increase, with the full-year FY2019 number at 0.62, down 8621.93% from a year prior.
  • Equity Ratio was 0.89 for Q3 2020 at Forte Biosciences, up from 0.88 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.89 in Q3 2020 to a low of 3.88 in Q1 2017.
  • A 5-year average of 0.16 and a median of 0.26 in 2018 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: tumbled 8621.93% in 2019, then soared 3039.5% in 2020.
  • Forte Biosciences' Equity Ratio stood at 3.52 in 2016, then surged by 121.94% to 0.77 in 2017, then tumbled by 100.92% to 0.01 in 2018, then crashed by 8621.93% to 0.62 in 2019, then soared by 243.55% to 0.89 in 2020.
  • Per Business Quant, the three most recent readings for FBRX's Equity Ratio are 0.89 (Q3 2020), 0.88 (Q2 2020), and 0.36 (Q1 2020).